We finally examined whether pharmaceutical inhibition of TWIST1, the end-product of the STAT3-MKL1 transcriptional axis, would be sufficient to attenuate EndMT and liver fibrosis. The gene discussed is TWIST1; the disease is Hepatic fibrosis.